A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Antiviral Activity of GS-9688 in Viremic Adult Subjects With Chronic Hepatitis B Who Are Not Currently on Treatment

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Oct 2019

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selgantolimod (Primary) ; Tenofovir alafenamide
Indications Hepatitis B
Focus Pharmacodynamics
Sponsors Gilead Sciences

Most Recent Events

03 Oct 2019 Planned End Date changed from 1 Apr 2020 to 1 Apr 2021.
30 Jul 2019 Status changed from recruiting to active, no longer recruiting.
06 Jun 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2019.

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Welcome to AdisInsight